GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (STU:18C) » Definitions » EPS without NRI

GB Sciences (STU:18C) EPS without NRI : €-0.00 (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is GB Sciences EPS without NRI?

GB Sciences's earnings per share without non-recurring items for the three months ended in Sep. 2024 was €0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for GB Sciences's EPS without NRI or its related term are showing as below:

STU:18C' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -82.7   Med: 28.3   Max: 78
Current: 28.6

STU:18C's 3-Year EPS without NRI Growth Rate is ranked better than
77.8% of 1239 companies
in the Biotechnology industry
Industry Median: 4.6 vs STU:18C: 28.60

GB Sciences's EPS (Diluted) for the three months ended in Sep. 2024 was €0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.00.

GB Sciences's EPS (Basic) for the three months ended in Sep. 2024 was €0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.00.


GB Sciences EPS without NRI Historical Data

The historical data trend for GB Sciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences EPS without NRI Chart

GB Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.01 -0.01 - -

GB Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GB Sciences's EPS without NRI

For the Biotechnology subindustry, GB Sciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GB Sciences's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where GB Sciences's PE Ratio without NRI falls into.



GB Sciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GB Sciences  (STU:18C) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


GB Sciences EPS without NRI Related Terms

Thank you for viewing the detailed overview of GB Sciences's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


GB Sciences Business Description

Traded in Other Exchanges
Address
9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments. The company's intellectual property covers various medical conditions, from which five drug development programs are in the preclinical stage of drug development including its formulations for Parkinson's disease (PD), chronic pain, cytokine release syndrome, depression, and cardiovascular therapeutic programs.

GB Sciences Headlines

No Headlines